+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Spasticity Epidemiology Forecast 2025-2034

  • PDF Icon

    Report

  • 150 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102503
Spasticity is estimated to affect more than 12 million individuals worldwide, including around 80% of people with multiple sclerosis and 80% of cerebral palsy patients. Spasms, involuntary contractions, and muscle stiffness are some of the common symptoms of spasticity.

Spasticity Epidemiology Forecast Report Coverage

The “Spasticity Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of spasticity. It projects the future incidence and prevalence rates of spasticity across various populations. The study covers age and type as major determinants of the spasticity-affected population. The report highlights patterns in the prevalence of spasticity over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of spasticity in the 8 major markets.

Regions Covered

  • The United States
  • Germany
  • France
  • Italy
  • Spain
  • The United Kingdom
  • Japan
  • India

Spasticity: Disease Overview

Spasticity refers to a form of hypertonia characterized by abnormal muscle tightness or stiffness. The condition can make it difficult to walk, speak, move, and perform other daily activities. Spasticity is caused by the disruption in communication between the spinal cord and brain and the muscles. It is considered a symptom of neurological conditions like stroke, cerebral palsy, spinal cord injury, multiple sclerosis, and traumatic brain injury, among others.

Spasticity: Treatment Overview

Oral medications like benzodiazepines, dantrolene sodium, tizanidine, imidazolines, baclofen, and gabapentin can aid in relieving symptoms of spasticity. Intrathecal medications such as phenol and baclofen, which are released into the cerebrospinal fluid with the help of a surgically placed pump, are also used as a treatment option. Additionally, occupational and physical therapy are also recommended to help improve mobility, muscle flexibility, and coordination.

Epidemiology

The spasticity epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for spasticity by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for spasticity and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.
  • Around 12 million individuals suffer from spasticity, with spasms, continuous muscle stiffness, and involuntary contractions being the common symptoms.
  • Studies show that spasticity is estimated to affect about 35% of people who experienced a stroke, over 90% of individuals with cerebral palsy, nearly 50% of the traumatic brain injury-affected population, 37 to 78% of multiple sclerosis patients, and 40% of people who have spinal cord injury.
  • As per an article published in the Journal of Stroke and Cerebrovascular Diseases (2020), the onset of spasticity is highly variable, with prevalence ranging from 4 to 43% and the incidence of disability estimated to be 2 to 13%.
  • The pooled incidence of spasticity post-stroke is reported to be 25.3%, according to a systematic review and meta-analysis published in the Frontiers in Neurology (2021).

Country-wise Spasticity Epidemiology

The spasticity epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of spasticity varies significantly between countries due to differences in the prevalence of underlying conditions such as stroke, multiple sclerosis, or cerebral palsy, advancements in healthcare infrastructure, and access to treatment, among others. In the United States, nearly 795,000 individuals are affected by stroke, out of which 25 to 43% of people are likely to experience spasticity in their first post-stroke year.

Scope of the Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of spasticity based on several factors.
  • Spasticity Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The report helps to identify the patient population, and the unmet needs of spasticity are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

  • What are the key findings of spasticity epidemiology in the 8 major markets?
  • What will be the total number of patients with spasticity across the 8 major markets during the forecast period?
  • What was the country-wise prevalence of spasticity in the 8 major markets in the historical period?
  • Which country will have the highest number of spasticity patients during the forecast period of 2025-2034?
  • Which key factors would influence the shift in the patient population of spasticity during the forecast period of 2025-2034?
  • What are the currently available treatments for spasticity?
  • What are the disease risks, signs, symptoms, and unmet needs of spasticity?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Spasticity Market Overview - 8 MM
3.1 Spasticity Market Historical Value (2018-2024)
3.2 Spasticity Market Forecast Value (2025-2034)
4 Spasticity Epidemiology Overview - 8 MM
4.1 Spasticity Epidemiology Scenario (2018-2024)
4.2 Spasticity Epidemiology Forecast
5 Disease Overview
5.1 Signs and Symptoms
5.2 Causes
5.3 Risk Factors
5.4 Guidelines and Stages
5.5 Pathophysiology
5.6 Screening and Diagnosis
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
7 Epidemiology Scenario and Forecast - 8 MM
7.1 Key Findings
7.2 Assumptions and Rationale
7.3 Spasticity Epidemiology Scenario in 8MM (2018-2034)
8 Epidemiology Scenario and Forecast: United States
8.1 Spasticity Epidemiology Scenario and Forecast in the United States (2018-2034)
9 Epidemiology Scenario and Forecast: United Kingdom
9.1 Spasticity Epidemiology Scenario and Forecast in United Kingdom (2018-2034)
10 Epidemiology Scenario and Forecast: Germany
10.1 Spasticity Epidemiology Scenario and Forecast in Germany (2018-2034)
11 Epidemiology Scenario and Forecast: France
11.1 Spasticity Epidemiology Scenario and Forecast in France
12 Epidemiology Scenario and Forecast: Italy
12.1 Spasticity Epidemiology Scenario and Forecast in Italy (2018-2034)
13 Epidemiology Scenario and Forecast: Spain
13.1 Spasticity Epidemiology Scenario and Forecast in Spain (2018-2034)
14 Epidemiology Scenario and Forecast: Japan
14.1 Spasticity Epidemiology Scenario and Forecast in Japan (2018-2034)
15 Epidemiology Scenario and Forecast: India
15.1 Spasticity Epidemiology Scenario and Forecast in India (2018-2034)
16 Patient Journey17 Treatment Challenges and Unmet Needs18 Key Opinion Leaders (KOL) Insights